CIDP

(redirected from Chronic inflammatory demyelinating polyneuropathy)
Also found in: Dictionary, Medical, Acronyms, Wikipedia.

CIDP

Crop Insurance and Disaster Payments. Any payments one receives from an insurance policy covering agricultural real estate. One lists CIDP on Form 4835 or Schedule F.
References in periodicals archive ?
For more information about the new, peer-reviewed Chronic Inflammatory Demyelinating Polyneuropathy Information Center, please visit http://www.
Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population.
Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy.
GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market.
Chronic inflammatory demyelinating polyneuropathy is a neurological disorder often characterized by progressive weakness and impaired sensory function in the legs and arms.
Gamunex is indicated as replacement therapy of primary humoral immunodeficiency disease (PI) and as immunomodulatory therapy for idiopathic thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Food and Drug Administration (FDA) approved Gamunex for the treatment of a neurological condition, chronic inflammatory demyelinating polyneuropathy (CIDP), to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.
ROTTERDAM, Netherlands, June 27, 2012 /PRNewswire/ -- Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen[Immune Globulin Intravenous (Human), 10% Liquid], an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Sub-analysis from a Phase III study of patients with a neurological disease, chronic inflammatory demyelinating polyneuropathy (CIDP), suggest that therapy with Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) may improve their physical and social functioning compared to placebo.
March 26, 2012 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Stories are showcased from patients and families who are affected by Batten's Disease, CIDP, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Variable Immune Deficiency (CVID), Citrullinemia, Cystinuria, Epidermolysis Bullosa, Fibromuscular Dysplasia, Gaucher's Disease, Hunter Syndrome, Huntington's Disease, Joubert Syndrome, Kleefstra Syndrome, Langerhans cell histiocytosis (LCH), Lennox-Gastaut Syndrome, Maple Syrup Urine Disease, Marfan Syndrome, Mitochondrial Myopathy, Moebius Syndrome, Nager Syndrome, Neimann Pick Type C, Pallister-Killian Syndrome, Primary Immune Deficiency Disease (PIDD), Pseudotumor Cerebri, Sanfilippo Syndrome, Spina Bifida and more.
Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
Full browser ?